Rosetta Genomics (NASDAQ: ROSG) is one of 184 public companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its competitors? We will compare Rosetta Genomics to similar companies based on the strength of its institutional ownership, profitability, risk, valuation, dividends, earnings and analyst recommendations.
Insider & Institutional Ownership
8.3% of Rosetta Genomics shares are held by institutional investors. Comparatively, 49.3% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 14.7% of shares of all “Biotechnology & Medical Research” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This is a breakdown of current ratings for Rosetta Genomics and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Rosetta Genomics Competitors||535||2357||6430||124||2.65|
Rosetta Genomics currently has a consensus target price of $3.50, suggesting a potential upside of 446.88%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 18.02%. Given Rosetta Genomics’ stronger consensus rating and higher possible upside, research analysts plainly believe Rosetta Genomics is more favorable than its competitors.
This table compares Rosetta Genomics and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Rosetta Genomics Competitors||-3,403.58%||-548.25%||-40.43%|
Valuation & Earnings
This table compares Rosetta Genomics and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Rosetta Genomics||$9.23 million||-$16.23 million||-0.06|
|Rosetta Genomics Competitors||$217.29 million||-$39.39 million||-54.78|
Rosetta Genomics’ competitors have higher revenue, but lower earnings than Rosetta Genomics. Rosetta Genomics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Risk and Volatility
Rosetta Genomics has a beta of 0.31, meaning that its stock price is 69% less volatile than the S&P 500. Comparatively, Rosetta Genomics’ competitors have a beta of 1.53, meaning that their average stock price is 53% more volatile than the S&P 500.
Rosetta Genomics beats its competitors on 7 of the 12 factors compared.
About Rosetta Genomics
Rosetta Genomics Ltd. is engaged in developing and commercializing new diagnostic tests based on various genomics markers, including deoxyribonucleic acid (DNA), micro ribonucleic acid (microRNA) and protein biomarkers and using various technologies, including, Quantitative polymerase chain reaction (qPCR), microarrays, Next Generation Sequencing (NGS) and Fluorescence In Situ Hybridization (FISH). It is marketing and selling over four diagnostic tests based on its microRNA technologies, which include RosettaGX Cancer Origin, mi-LUNG, mi-KIDNEY and RosettaGX Reveal. Its therapeutic pipeline consists of the projects, which include Rimonim Consortium and Magneton Project. It focuses on developing diagnostic assay, RosettaGX Reveal V2. It is also focusing on developing Bladder cancer risk stratification. Its PersonalizeDx is focused on the detection of genomic changes through FISH technology, which helps to detect cancer.
What are top analysts saying about Rosetta Genomics Ltd.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Rosetta Genomics Ltd. and related companies.